Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Divergent effects of distinct perivascular cell subsets for intra-articular cell therapy in posttraumatic osteoarthritis.

Hsu GC., Cherief M., Sono T., Wang Y., Negri S., Xu J.

Animal Study on Osteoarthritis, Cartilage Damage, Meniscus Injury, published in J Orthop Res (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Orthop Res (2021)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
33512030
DOI
10.1002/jor.24997

Abstract (original English)

Intra-articular injection of mesenchymal stem cells has shown benefit for the treatment of osteoarthritis (OA). However, mesenchymal stem/stromal cells at the origin of these clinical results are heterogenous cell populations with limited cellular characterization. Here, two transgenic reporter mice were used to examine the differential effects of two precisely defined perivascular cell populations (Pdgfrα + and Pdgfrβ + cells) from white adipose tissue for alleviation of OA. Perivascular mesenchymal cells were isolated from transgenic Pdgfrα-and Pdgfrβ-CreER T2 reporter animals and delivered as a one-time intra-articular dose to C57BL/6J mice after destabilization of the medial meniscus (DMM). Both Pdgfrα + and Pdgfrβ + cell preparations improved metrics of cartilage degradation and reduced markers of chondrocyte hypertrophy. While some similarities in cell distribution were identified within the synovial and perivascular spaces, injected Pdgfrα + cells remained in the superficial layers of articular cartilage, while Pdgfrβ + cells were more widely dispersed. Pdgfrβ + cell therapy prevented subchondral sclerosis induced by DMM, while Pdgfrα + cell therapy had no effect. In summary, while both cell therapies showed beneficial effects in the DMM model, important differences in cell incorporation, persistence, and subchondral sclerosis were identified.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCartilage, ArticularCell- and Tissue-Based TherapyDisease Models, AnimalInjections, Intra-ArticularMiceMice, Inbred C57BLMice, TransgenicOsteoarthritisReceptor, Platelet-Derived Growth Factor alpha

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research